Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. (ZTEK) generates news across several advanced technology domains, reflecting its role as an intellectual property development and commercialization company. Its disclosures highlight activity in graphene-based coatings, critical mineral development, aptamer-based healthcare technologies and fire-retardant materials, giving investors and observers multiple streams of company-specific updates.
A major news theme is Zentek’s work through its wholly owned subsidiary Albany Graphite Corp. on the Albany Graphite Project in Ontario. Recent releases describe ultra-high purity Albany graphite reaching five-nines carbon purity with an Equivalent Boron Concentration below thresholds generally referenced for nuclear applications, as well as additional nuclear suitability testing and independent verification using near-net-shaped graphite bricks. Separate announcements cover lithium-ion battery suitability testing, where spheroidized Albany graphite has shown near-theoretical anode performance under industry-standard conditions.
Another recurring topic is Zentek’s ZenGUARD™ platform for surgical masks and HVAC air filters, including corporate updates on testing under the Government of Canada’s Innovative Solutions Canada program and efforts to advance ZenGUARD™ Enhanced Air Filters in Canada and international markets. News items also address the company’s development of a Graphite Gel-Based Fire-Retardant product and an exclusive licensing arrangement with Altek Advanced Materials Inc. for commercialization in the United States.
Healthcare-focused news includes progress on multivalent aptamer countermeasures against influenza through Triera Biosciences and McMaster University, supported by a federal testing contract. Corporate governance and capital markets developments, such as CEO transitions, board appointments, annual meeting voting results and tax reassessment matters, are reported through regular press releases and associated Form 6-K filings. Readers following ZTEK news can expect updates on technology milestones, regulatory and testing programs, strategic partnerships and key corporate decisions.
Zentek (NASDAQ:ZTEK) has announced promising preliminary results from its first in vivo tests of an influenza countermeasure candidate using multivalent aptamer technology. The testing, conducted at McMaster University, showed that animals treated with the aptamer lead candidate demonstrated 5x greater survival rates and 80% less weight loss compared to the control group.
The project, supported by a $1.1 million grant from the Government of Canada's Innovative Solutions Canada Testing Stream, aims to develop both prophylactic and therapeutic countermeasures for seasonal influenza (H1N1) and highly pathogenic avian influenza (H5N1). The aptamer countermeasure has shown strong binding affinities for multiple influenza strains (H1, H5, H2, and H3) and demonstrated effective neutralization against H1N1 and H5N1 in vitro.
Zentek (NASDAQ:ZTEK) has announced updates to its slate of director nominees for the upcoming annual general and special meeting scheduled for September 25, 2025. The company has nominated four independent directors: current Board Chair Eric Wallman, current director John Snisarenko, and two new nominees - Matt Fontes and Pete Gettinby.
Current directors Ilse Treurnicht, Lisa Sim, and Wendy Ford will not stand for re-election. The meeting location has been changed to Norton Rose Fulbright Canada LLP's office in Toronto. Shareholders must use the new "BLUE" proxy form for voting, as previous "WHITE" forms will not be counted.
Zentek (Nasdaq:ZTEK) announced the immediate resignation of CEO Greg Fenton, who will transition to lead Altek Advanced Materials, a U.S.-based private company where he holds over 50% equity interest. The company has entered into a non-exclusive licensing agreement LOI with Altek for commercializing Zentek's technologies, including ZenGUARD™, in the United States.
The LOI includes a 5-year initial term with a 5-year renewal option and royalties between 5-8% of net sales. CFO Wendy Ford will serve as interim CEO while the board conducts a comprehensive search for a permanent replacement. Fenton will join Zentek's Advisory Board and continue providing strategic guidance through his Consulting Agreement until March 31, 2026.
Zentek (Nasdaq:ZTEK) announced changes to its Board of Directors. Ilse Treurnicht has resigned from the Board effective immediately but will continue serving on the Zentek Advisory Board. John Snisarenko has been appointed as Company Secretary and Chair of the Corporate Governance, Compensation and Nominating Committee.
Additionally, Lisa Sim will not stand for re-election as director but will join the Advisory Board to continue managing the company's intellectual property portfolio. The Board is reviewing new nomination candidates proposed by shareholders. The company will amend and re-mail proxy voting information for the upcoming annual and special meeting scheduled for September 25, 2025.
Zentek (NASDAQ:ZTEK) announced its subsidiary Albany Graphite Corp. (AGC) has been awarded a $500,000 grant from Ontario's Critical Minerals Innovation Fund for graphite purification and anode development. The project includes $314,500 contribution from AGC and $200,000 in-kind support from Natural Resources Canada.
The project aims to produce 5-6 tonnes of flotation concentrate and involves testing with NRCan's electrothermal fluidized bed reactor. AGC recently achieved a significant milestone with 99.9991% purity in preliminary testing, notably without using chlorine gas. The company is positioning itself in the North American battery supply chain, with potential applications in EV batteries, which require up to 125 kg of graphite per vehicle.
Zentek Ltd. (Nasdaq: ZTEK) has received notification from Nasdaq that it is not compliant with the minimum bid price requirement, as its shares have traded below US$1.00 for 31 consecutive business days. The company has until February 23, 2026 to regain compliance by maintaining a closing bid price of at least US$1.00 for 10 consecutive business days.
If Zentek fails to meet this deadline, it may be eligible for an additional 180-day grace period if it meets other listing requirements and provides written notice to Nasdaq. The notification is not an immediate delisting notice, and the company's shares continue to trade on the Nasdaq Capital Market while management explores options to regain compliance.
Zentek (NASDAQ:ZTEK) announced that CEO Greg Fenton's consulting contract will not be extended beyond its expiration date of March 31, 2026. The board of directors has initiated a search for his successor, while the current executive team continues to lead the company in the interim.
Fenton served as CEO for seven years, during which he guided the company's growth and diversification. The board emphasized its commitment to appointing a new CEO who will focus on transitioning Zentek from research and development to commercialization.
Zentek (NASDAQ:ZTEK) announced a regulatory update regarding its ZenGUARD™ Enhanced Air Filters in Canada. Health Canada is currently evaluating the product's classification and has requested additional information from the company.
Previously, on October 31, 2024, Zentek had withdrawn its submission from the Health Canada Pest Management Regulatory Agency (PMRA) to pursue an alternative commercialization pathway. The company subsequently announced on November 27, 2024, its intention to market the air filters as a Class I medical device under its existing Medical Device Establishment License (MDEL), similar to its surgical masks.
Zentek (NASDAQ:ZTEK) has signed a three-year agency agreement with RSK Environment Ltd. on May 7, 2025, enabling RSK to market and promote ZenGUARD™ Enhanced Air Filters in over 20 countries. The partnership focuses on key global markets, including the Gulf Cooperation Council (GCC) region. Under the agreement, Zentek maintains manufacturing and fulfillment responsibilities, while RSK receives a fixed commission on sales within designated territories.
This partnership complements Zentek's existing agreements with Saudi-based Filtration Solutions Industrial Co. and Levidian, strengthening the company's presence in the GCC region. The collaboration aims to align advanced HVAC filtration solutions with regional sustainability and infrastructure objectives.
FAQ
What is the current stock price of Zentek (ZTEK)?
What is the market cap of Zentek (ZTEK)?
